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(DRG), and more Medicare dollars are spent annually for
diagnosis and treatment of HF than for any other DRG
with estimated total direct and indirect costs of almost
$28 billion.1,2
As the disease progresses, HF patients lose the ability
to carry out activities of daily living. A task force for the
American College of Cardiology/American Heart
Association recently made the following statement, “The
implementation of therapies demonstrated to slow the
progression of HF is imperative.” We, as nutrition support
clinicians, need to do everything within our power to
improve the nutrition status, quality of life (QOL), and
clinical outcomes of HF patients.
The development of cardiac cachexia and protein-
calorie malnutrition in patients with HF puts them at
risk for multiple nutrient deficiencies. A recent study
concluded that the use of a multimicronutrient supple-
ment, containing 200 mg thiamin/day improved QOL
and left ventricular ejection fraction (LVEF) in elderly
HF patients.5 However, the specific role thiamin may
have played in these outcomes is difficult to determine.
Thiamin is of particular interest in the management of
HF for several reasons: (a) HF is a disease of the elderly
whose micronutrient status is in need of attention;
(b) HF patients tend to have inadequate nutrient intake,
which has been associated with thiamin deficiency;
(c) thiamin deficiency (wet beriberi) impairs cardiac
performance and can mimic the signs and symptoms of
Approximately 5 million people in the United Statessuffer from heart failure (HF), and more than550,000 people are diagnosed with this condition
each year.1,2 The aging population and the prolongation of
life secondary to modern therapeutic innovations in car-
diology and cardiothoracic surgery for HF patients have
led to a significant increase in the reported incidence of
HF, which is approaching 10 in 1000 people older than
65 years of age.1,2 In the United States, HF results in
12–15 million office visits and 6.5 million hospital days
each year.2,3
Despite therapeutic advancements in the medical
management of HF with the use of angiotensin-converting
enzyme (ACE) inhibitors, β-blockers, nonglycoside
inotropic agents, and loop diuretics (ie, furosemide,
bumetanide, etc.), as well as new surgical techniques
designed to improve the structure and function of the
heart, the disability and mortality rates associated with
this disease are staggering.4 The costs in terms of
resources and expenses associated with the management
of HF are also significant. In U.S. healthcare, HF is the
most commonly used Medicare diagnosis-related group
Heart failure (HF) is a major public health problem in the
United States that puts a significant burden on both patients
and the healthcare system. The prevalence of malnutrition in
HF patients is well-known and correlates with a dramatic
decline in quality of life and disease progression, and is associ-
ated with high morbidity and mortality rates. The implication of
HF on micronutrient status is underrecognized in the quest to
offer “best practice” medical, device, and surgical interventions
to this population. The micronutrient thiamin is of particular
interest in the management of HF for several reasons: (a) HF is
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attention; (b) HF patients tend to have inadequate nutrient
intake, which has been associated with thiamin deficiency;
(c) thiamin deficiency (wet beriberi) impairs cardiac performance
and can mimic the signs and symptoms of HF thereby poten-
tially exacerbating the underlying disease; (d) use of loop diuret-
ics to manage fluid and sodium imbalances associated with HF
may cause the hyperexcretion of thiamin, thereby increasing the
risk of deficiency; and (e) the prevention of thiamin deficiency
should be a routine component in the overall management of
this disease. (Nutr Clin Pract. 2008;23:487-493)
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HF thereby potentially exacerbating the underlying
disease6-10; (d) use of loop diuretics to manage fluid and
sodium imbalances associated with HF may cause the
hyperexcretion of thiamin, thereby increasing the risk of
deficiency; and (e) the prevention of thiamin deficiency
should be a routine component in the overall manage-
ment of this disease. The purpose of this review is to
increase awareness in the nutrition community regarding
several characteristics of thiamin and to discuss the
relevance of its deficiency to HF patients.
Characteristics of Thiamin
History
Once referred to as the anti-beriberi factor and called
“vitamine” for its “vital amine” properties, thiamin was
first isolated in 1926 by 2 Dutch chemists, Dr B. C. P.
Jansen and Dr W. Donath.11 Initially, they named it
aneurin after antineuritic vitamin.11 Long before thi-
amin was given its current name, correctly identified,
isolated, and synthesized in a clinical laboratory by
Dr R. R. Williams, the disorder associated with thiamin
deficiency was rampant in many parts of the world,
especially in Asia. This disorder appeared after the intro-
duction of polished rice into the diets of Asians. In the
late 1800s, Dr K. Takaki first documented that beriberi
seemed to be a nutrient deficiency after they were able
to decrease the incidence of beriberi from 40% to 0% in
6 years by giving Japanese sailors a high-protein, low-
carbohydrate diet consisting of vegetables, barley, fish,
and meat at the expense of rice in daily rations. Dr
Gerril Grijns had a different theory. He postulated that
polished rice was lacking a specific, “substance of
importance,” in central nervous system metabolism.11
His colleague, Dr Christian Eijkman, another Dutch
physician, showed that a polyneuropathy could be
induced in chicks eating polished rice and cured when
the polishings were refed to them.
Chemical Properties
Thiamin, also referred to as thiamine and B1, is a water-
soluble and colorless vitamin with a characteristic odor
and slightly bitter taste.10-12 The chemical description for
thiamin is 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-
5-(2-hydroxyethyl)-4-methylthiazolium. The chemical
structure of thiamin (Figure 1) consists of a pyrimidine
ring connected to a thiazole ring by a 1-carbon link. The
nitrogen atom within the thiazole ring serves many func-
tions as an important electron sink in thiamin pyrophos-
phate (TPP)-catalyzed reactions.11,12
Thiamin exists in 3 forms: thiamin monophosphate
(TMP), thiamin triphosphate (TTP), and thiamin
pyrophosphate (TPP). Thiamin pyrophosphate is also
known as thiamin diphosphosphate (TDP), which is the
biologically active form of thiamin.8,10 Thiamin pyrophos-
phate is an intracellular compound, which is why it pro-
vides the best expression of thiamin status.10 Thiamin
rarely exists in free form but, as such, travels in the
serum. Thiamin is heat-stable and oxygen-stable in its dry
form but is unstable in alkaline solution and decomposi-
tion is accelerated by light and increased temperature.12
Biochemical Functions
Thiamin in its various forms functions as a coenzyme for
macronutrient oxidation and the production of adenosine
triphosphate.13 Thiamin pyrophosphate works in conjunc-
tion with magnesium to facilitate several oxidative decar-
boxylation reactions. Thiamin pyrophosphate is a catalyst
in the reactions of pyruvate to acetyl CoA and α-ketoglu-
tarate to succinyl CoA in the Krebs cycle. The pentose
phosphate pathway (PPP) serves as a metabolic pathway
within the cell to produce fuel and store it in the form of
NADPH (reduced nicotinamide adenine dinucleotide
phosphate; Figure 2). Thiamin pyrophosphate plays an
important role in this central pathway for energy produc-
tion and the creation of riboses used for RNA and DNA
synthesis.12 Another enzyme within the PPP that TPP
functions as a coenzyme with is transketolase. A 2-carbon
unit from an α-ketose is transferred to an aldose by trans-
ketolase (Figure 2).
Thiamin is found in both the nerves and brain tissue.8
The role of thiamin in neurophysiology is unclear, but it
seems to be important independent of its role as a coen-
zyme. It appears that TPP is involved in the sodium-
dependent and potassium-dependent gradients that
stimulate nerve impulses.11
Food and Supplemental Sources
Thiamin is widely distributed in foods (Table 1), but its
content in most foods is relatively low.12 As whole grains
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Figure 1. Chemical structure of thiamin.
are processed, they lose their naturally occurring thiamin
content. However, the enrichment of refined flour allows
the nutrition quality to be returned to original levels.
Thiamin supplements are available in several forms
with the most common being thiamin hydrochloride and
thiamin mononitrate, both of which are water-soluble.
S-benzyolthiamine-O-monophosphate is a synthetic derivative
of thiamin that is fat-soluble. Although not commonly
used in practice, S-benzyolthiamine-O-monophosphate is
more bioavailable and physiologically active than other
sources of thiamin and may induce a better thiamin
response in patients than other forms. Typically, thiamin
supplements are manufactured and distributed in 50 or
100 mg doses even though the recommended dietary
intake (RDI) is much lower (Table 2).
Thiamin Absorption
Thiamin is absorbed in the jejunum of the small intestine
by an active transport process that is likely carrier-mediated
against a concentration gradient at low concentrations.12
At high concentrations, absorption takes place by passive
diffusion.12 Phosphorylation takes place in the jejunal
mucosa to yield TPP. Maximum absorption of thiamin by
the gut is 5 mg (Table 2). Thiamin is carried by portal
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Figure 2. Thiamin pyrophosphate (TPP) in the pentose phosphate pathway.
Table 1. Thiamin Food Sources
Grains—wheat, wheat germ, dried yeast, oats, rice, cereal
products, bread, pasta




Milk and milk products
Orange and tomato juice
Pizza
Vegetables—beets, green leafy vegetables, potatoes
Legumes—lentils, soy beans, nuts, and seeds
blood to the liver and transported into red blood cells
(RBCs) by a facilitated diffusion process.12 Thiamin has a
quick turnover rate and is not stored in large amounts;
therefore, a continuous supply is necessary.12 Approxi-
mately 30 mg of thiamin are stored in the body (Table 2)
with 80% as TPP and the rest as TMP. About 50% of
the body stores are found in skeletal muscles with the
remainder in the heart, liver, kidney, and tissue of the
nervous system, including the brain.10
Thiamin Excretion
Thiamin, in excess of systemic tissue demand and storage
capacity, is excreted in the urine.10 As thiamin deficiency
develops, there is a rapid loss of the vitamin from all tis-
sues except the brain. The decrease of TPP in RBCs
roughly parallels the decrease of this coenzyme in other
tissues. During this time, urinary excretion of thiamin
falls close to zero in order to preserve endogenous stores.
Signs and Symptoms of Thiamin Deficiency
Specific signs and symptoms observed in thiamin-deficient
patients represent alterations in the biochemistry of
thiamin that result in impaired oxidative phosphorylation,
increased levels of proximal metabolites (pyruvate), and
decreased transketolase activity in RBCs, liver, heart, and
other organs.12
Thiamin deficiency manifests as dry or wet beriberi.
Dry beriberi involves peripheral neuropathy that can be
permanent even following thiamin repletion.14,15
Neurological side effects of thiamin deficiency can
progress to Wernicke–Korsakoff syndrome. In general,
patients with thiamin deficiency experience the “classic
triad” of symptoms, including oculomotor abnormalities,
gait disturbance, and global confusion.14 However, all
these symptoms do not need to be present to make a diag-
nosis of Wernike–Korsakoff syndrome.
Wet beriberi impairs cardiac performance and typi-
cally presents as peripheral dilation, high-output cardiac
failure, biventricular low-output failure, and sodium and
water retention.7 This syndrome mimics the signs and
symptoms of HF; therefore, thiamin deficiency may actu-
ally exacerbate underlying HF. In fact, research has
shown that when thiamin deficiency is corrected, LVEF
improves.6,16-18 Ejection fraction is one of the most widely
used predictors of prognosis; patients with reduced LVEF
typically have poor outcomes. The presumed mechanism
by which thiamin deficiency exacerbates HF is through
the inhibition of the pyruvate dehydrogenase complex.19,20
Inhibition of pyruvate dehydrogenase complex has been
theorized to decrease the efficiency of adenosine triphos-
phate production, increase cellular acidosis, and increase
free fatty acid levels in circulation.19,20
Thiamin deficiency can occur within 14 days of
inadequate status.10 Although rare, the most extreme
and life-threatening form of thiamin deficiency is
shoshin beriberi, a fulminant form of wet beriberi that
can ensue quite rapidly resulting in acute cardiovascular
collapse, metabolic acidosis, and death within hours.13
Rapid recovery is achieved within hours following intra-
venous thiamin administration.20,21 Therefore, thiamin
deficiency should routinely be considered during diag-
nostic evaluations.
Mechanisms Contributing to
Thiamin Deficiency in HF Patients
There are several mechanisms that can contribute to
thiamin deficiency in HF patients (Table 3). Subclinical
thiamin deficiency may occur with age or during situations
that cause hypermetabolism, that is, trauma, surgery, or
fever.22 Other high-risk populations include the elderly,
alcoholics, people with HIV/AIDS, homeless individuals,
patients with frequent hospitalizations, and those with
persistent vomiting, diarrhea/malabsorption syndromes,
and dietary inadequacy.7,8,10
The issue of age as a factor contributing to the preva-
lence of thiamin deficiency was evaluated by Levy et al16
who conducted a prospective trial of patients with a mean
age of 47 ± 10 years, mean New York Heart Association
(NYHA) functional class of 2.5 ± 0.6 on a scale of I-IV,
and mean LVEF of 22 ± 9% (normal LVEF >50%8). The
mean dosage of loop diuretics (mainly furosemide) was
184 mg/day. Thiamin status was measured by erythrocyte
transketolase activity. No evidence of thiamin deficiency
was found in their population of HF patients.16 Given the
relatively young age of the subjects used in this study, it
may be that other factors in an older HF population con-
tribute to the risk of thiamin deficiency such as disease
severity, comorbidity, dietary inadequacy, and drug–nutrient
interactions.
A drug–nutrient interaction has been shown to occur
between loop diuretics and thiamin. Historically, loop
diuretics were approved for the general treatment of ede-
matous disorders. Even though they have never been pri-
marily evaluated for the treatment of HF, loop diuretics
are used to counteract HF through the renal excretion of
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Table 2. Thiamin Supplementation Considerations
Recommended dietary intake 1-1.5 mg/day
Maximum jejunal absorption 5 mg/day
Storage capacity 30 mg
Standard dose in multivitamin 1 mg/day
Standard dose in single vitamin 50-200 mg/day
Estimated cost of intravenous thiamin $0.25/100 mg dose
Estimated cost of oral thiamin $0.03/100 mg dose
Risk of toxicity Low
sodium, chloride, and water along with other water-soluble
molecules, including potassium, magnesium, vitamin C, and
vitamin B-complex vitamins, such as thiamin.10 Increased
losses of thiamin secondary to loop diuretic therapy was
first described in 1980 by Yiu et al.23 Since then, several
other studies have replicated these findings suggesting
that loop diuretic therapy can lead to thiamin deficiency
secondary to hyperexcretion.6-9
Inadequate caloric and protein intake is common in
HF patients8,24 and the diets of patients with HF often do
not contain adequate amounts of thiamin-rich foods.7,8
Kwok et al22 reported that poor appetite is a reliable indi-
cator of compromised thiamin status in elderly patients
with HF. Reasons that oral intake in HF patients may be
marginal include early satiety, a sensation of fullness,
cachexia, changes in the thirst mechanism, sodium-
restrictive and fluid-restrictive diets that may result in the
avoidance of thiamin-rich foods, lack of motivation,
malaise, and poor mobility.
Treatment of Thiamin Deficiency
The U.S. RDI is 1 mg/day for women and 1.2–1.5 mg/day
for men, but thiamin requirements are contingent on
energy expenditure and carbohydrate intake. Typical reple-
tion regimens in the acute clinical setting range from
50–200 mg/day intravenously or orally (Table 2) with rapid
clinical improvement following supplementation.10,13 For
mild neuropathy, 10–20 mg oral thiamin per day is recom-
mended for 2 weeks.25 Moderate or advanced neuropathy
can be treated with a dose of 20–30 mg/day for several
weeks after symptoms disappear.25 For edema and conges-
tion due to wet beriberi, 100 mg intravenous (IV) thiamin
per day is given for several days.25 For Wernicke–Korsakoff
syndrome, 50–100 mg intramuscular or IV thiamin should
be given twice daily for several days followed by 10–20 mg
per day until a therapeutic response is observed.25
Improvement in patients with Korsakoff psychosis may
take 1–3 months, and recovery from neurologic deficits is
often incomplete.25
The cost of thiamin supplementation is low as is the
risk of toxicity (Table 2).13 In general, thiamin is con-
sidered safe and relatively nontoxic even at high doses.
An upper level of tolerance has not been established.
Large doses can result in fatigue or muscle relaxation,
but dermatitis or anaphylactic reactions rarely occur.26
Thiamin injections may cause a burning sensation,
which can often be avoided by slow administration into
larger veins.26
Assessment of Thiamin Status
Serum and Urinary Thiamin Levels
The half-life of serum thiamin is short and only reflects
immediately preceding oral intake. This inhibits its use as
a reliable indicator of thiamin status. Thiamin urinary
excretion, even when normalized for urinary creatinine
concentration, also has limitations as a sensitive indicator
of thiamin status because, aside from its cumbersome
nature due to a required loading dose and 24-hour urine
collection, urinary thiamin concentrations reflect recent
oral intake. If urinary thiamin levels increase following
the loading dose, as measured with high-performance liq-
uid chromatography (HPLC) using the methods of
Botticher and Botticher,27 status is intact. If no change in
urinary thiamin content is observed, this is suggestive of
the body’s need for it and the risk of subclinical deficiency
exists. One urinary thiamin metabolite that may be meas-
ured is thiochrome, but this method is no longer commonly
used in clinical practice.12
Erythrocyte Transketolase Activity Assay
The best measure for differentiating normal status from
subclinical thiamin deficiency is a functional enzymatic
test called the erythrocyte transketolase activity (ETKA)
assay. Erythrocytes, or RBCs, are used because they are
the first cells to reflect thiamin deficiency.10 The ETKA
assay is a thiamin-dependent enzymatic assay that meas-
ures ETKA and TPP effect (TPPE) through an in vitro
analysis of transketolase enzyme function. Exogenous
TPP is added, and if it has an effect on ETKA, the
response expressed as a percentage indicating normal,
mild, or severe thiamin deficiency proves whether
endogenous thiamin levels were deficient or not (Table
4). High-performance liquid chromatography is also used
in the research setting to evaluate ETKA and is probably
more sensitive than the ETKA functional enzymatic assay,
but it is not as practical.28
Erythrocyte Thiamin Pyrophosphate Analysis
The erythrocyte TPP analysis method directly measures TPP
using HPLC on an amino acid column.8,29 According to
Hanninen et al,8 this method is more specific than indirectly
measuring thiamin-dependent enzyme activity such as
ETKA. They defined thiamin deficiency as TPP < 78 ng/mL
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Table 3. Mechanisms Contributing to Thiamin
Deficiency in Heart Failure Patients






Thiaminases in certain foods (eg, tannins in tea)
Magnesium deficiency
Hyperthyroidism
packed cells based on the correlation between TPP and
the TPP effect.8,10
In clinical practice, the measurement of thiamin status
is unnecessary because a reliable test to measure thiamin
status is not readily available. Routine prophylactic thiamin
supplementation in HF patients is appropriate because it
offers protection from thiamin deficiency, and it is safe and
inexpensive with a low risk of side effects or toxicity.30
Prevalence of Thiamin
Deficiency in HF Patients
Animal Data—Review of Evidence
In 1980, Yiu et al16 first described the hyperexcretion of
thiamin as a consequence of loop diuretic therapy. Using
a rat model, they showed that the administration of loop
diuretics increased urinary thiamin excretion after 4
weeks of therapy and concluded that long-term diuretics
could induce deficiency. In a subsequent study also using
a rat model, loop diuretic therapy resulted in thiamin
deficiency in a dose-dependent response and was attrib-
uted to urinary hyperexcretion of this nutrient.31
Human Data—Review of Evidence
A wide range (21%–98%) in the prevalence of thiamin
deficiency has been documented in human subjects with
HF.6-9 The breadth of this range reflects variations in the
underlying nutrition status of subjects, presence of
comorbid conditions, concurrent use of medications,
including the type and dose of diuretics, reported use of
nutrition supplements, and measurement techniques for
the assessment of thiamin status.
Seligmann et al6 reported that 96% of patients (21 of
23) with HF receiving loop diuretic therapy (daily dose:
80–240 mg furosemide) developed thiamin deficiency.
Thiamin status was measured by TPPE and urinary thi-
amin excretion. Increased urinary losses of thiamin were
noted in 15–23 patients. The investigators also evaluated
the effect of thiamin supplementation on LVEF and
reported significant improvements in cardiac function
following thiamin repletion.6
Brady et al7 found that 21% of HF patients (8 of 38)
with NYHA class III/IV disease (mean LVEF 22 ± 8%)
receiving loop diuretic therapy (mean furosemide dose:
242 ± 216 mg/day) had thiamin deficiency based on
ETKA.7 They concluded that thiamin deficiency is prevalent
in outpatients with chronic HF but did not address uri-
nary thiamin excretion. Dietary assessment of thiamin
intake was conducted using a validated semiquantitative
food frequency checklist containing thiamin-rich foods to
estimate usual thiamin intake. Adequate thiamin intake
was defined as >30 servings/week; mild thiamin intake
inadequacy, 20–30 servings/week; and severe thiamin
intake inadequacy, <20 servings/week.7 They concluded
that marginal oral intake may increase the likelihood of
thiamin deficiency in HF patients.
Hanninen et al8 discovered that thiamin deficiency is
even more common in  HF inpatients compared with the
rate observed in chronic HF outpatients.8 Their study was
the largest study (n = 100) available using hospitalized
patients with a wide range of disease severity and vari-
ability in diuretic therapy (median dose of furosemide in
outpatients: 60 mg/day). Evidence of thiamin deficiency
was observed in one-third of subjects who acknowledged
the consumption of thiamin supplements.8 The preva-
lence of thiamin deficiency was positively correlated with
severity of disease. A total of 40% of patients with
advanced HF (NYHA class III/IV; LVEF <35%) were thi-
amin deficient compared with 25% of patients with
NYHA class I/II HF (LVEF >35%). This difference in
prevalence of thiamin deficiency was even higher when
supplement users were excluded with deficiency being
present in 49% of patients with LVEF <35% vs 24% of
patients with LVEF >35%.8
In contrast to the findings of Seligmann et al6 who
found that urinary excretion of thiamin was elevated in
HF patients on loop diuretics, Hanninen et al8 did not
detect a relationship between the development of thiamin
deficiency and diuretic use or urinary thiamin excretion.
Hanninen et al concluded that thiamin supplementation
is indicated, but that the thiamin content of a standard
multivitamin may be sufficient to protect against thiamin
deficiency.8
Conclusion
Although animal and human research related to the role of
thiamin in the management of HF is clinically significant,
studies have been limited by their small sample sizes, var-
ied use of measures of thiamin status, and inconsistencies
in the assessment of adequate intake. However, the rele-
vance of thiamin to cardiac function and cellular metabo-
lism is convincing.
Thiamin deficiency is prevalent in patients with HF
and yet this problem is underrecognized, preventable, and
easily treatable. Long-term routine thiamin supplemen-
tation may be protective against the manifestations of
thiamin deficiency, which mimics signs and symptoms of
HF exacerbation. Adequacy of thiamin intake should be
assessed in each HF patient. Measurement of thiamin
status is unnecessary. Minimally, NYHA class III and IV
492 Nutrition in Clinical Practice / Vol. 23, No. 5, October 2008
Table 4. Thiamin Pyrophosphate Effect
0%–15% improvement = no deficiency
16%–25% improvement = mild deficiency
>25% improvement = severe deficiency
HF patients with LVEF <50% on long-term loop diuretic
therapy should consume a multivitamin daily to promote
thiamin intake at the RDI level. Long-term use of higher
doses of thiamin, those of which are already commercially
available in 50–200 mg per dose amounts, deserve further
study. However, this dose of thiamin appears to be safe
and effective in the prevention of thiamin deficiency with
low risk of adverse side effects or toxicity at minimal
expense to both the patient and the healthcare system.
More research related to the safety and efficacy of
thiamin supplementation in HF patients is needed to
determine optimal dosing, duration of therapy, and clini-
cal outcomes. However, if the prophylactic administration
of thiamin supplements can decrease the prevalence of
thiamin deficiency, increase LVEF, and improve QOL,
it should be given without reservation to HF patients
who meet criteria in order to slow the progression of this
devastating disease.
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